BioCryst price target raised to $15 from $14 at Needham

Needham analyst Serge Belanger raised the firm’s price target on BioCryst (BCRX) to $15 from $14 and keeps a Buy rating on the shares. The company reported solid preliminary Q4 Orladeyo sales ahead of Street expectations, and the management expects its top-line to grow at 20% CAGR through 2027, implying annual Orladeyo sales increases of $90M-$95M, the analyst tells investors in a research note. The 2025 guidance combined with CAGR expectations for operating expense and the top-line set up significant profitability growth and cash generation starting in 2026, the firm adds.